Physician profile
Steven Osborn
NPI 1467867309
$153.68
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.95 · 2020: $23.02 · 2021: $79.57 · 2022: $16.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48.31 | 2019-2021 | |
| Novo Nordisk INC | $30.72 | 2021 | |
| Abbvie INC. | $23.48 | 2021 | |
| Terumo Medical Corporation | $21.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.60 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.